scholarly article | Q13442814 |
P356 | DOI | 10.1017/S1461145713000825 |
P698 | PubMed publication ID | 24103632 |
P50 | author | Jau-Shyong Hong | Q63384716 |
P2093 | author name string | Ru-Band Lu | |
I Hui Lee | |||
San-Yuan Huang | |||
Sheng-Yu Lee | |||
Shih-Heng Chen | |||
Shiou-Lan Chen | |||
Tzung Lieh Yeh | |||
Yen Kuang Yang | |||
Yun-Hsuan Chang | |||
Nian-Sheng Tzeng | |||
Liang-Jen Wang | |||
Chen-Lin Wang | |||
Chun-Hsieh Chu | |||
P2860 | cites work | Psychosocial Disability in the Course of Bipolar I and II Disorders | Q22253033 |
A rating scale for depression | Q24564540 | ||
Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior | Q24679793 | ||
The bipolar spectrum | Q28290726 | ||
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function | Q29615582 | ||
Development of a Rating Scale for Primary Depressive Illness | Q29616244 | ||
A rating scale for mania: reliability, validity and sensitivity | Q29619299 | ||
Neuroimaging in bipolar disorder: what have we learned? | Q30615539 | ||
The evolving bipolar spectrum. Prototypes I, II, III, and IV. | Q33768203 | ||
Neuroimaging studies of mood disorders | Q33924331 | ||
Exercise: a behavioral intervention to enhance brain health and plasticity | Q33959877 | ||
Pharmacogenetics of psychotropic drug response | Q33977981 | ||
Models for longitudinal data: a generalized estimating equation approach | Q34170659 | ||
A diagnostic interview: the schedule for affective disorders and schizophrenia | Q34269355 | ||
Effects of BDNF polymorphisms on antidepressant action. | Q34497530 | ||
The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial | Q34633307 | ||
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder | Q34871885 | ||
Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects | Q35016570 | ||
Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats | Q36725510 | ||
Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. | Q36848206 | ||
Bipolar II disorder: arguments for and against a distinct diagnostic entity | Q37058584 | ||
Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants | Q37133128 | ||
The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. | Q37219127 | ||
Pharmacogenomics of antidepressant drugs | Q37535096 | ||
Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis | Q37873034 | ||
The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence | Q38025454 | ||
Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode | Q39270744 | ||
Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients | Q40318595 | ||
Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain | Q40771649 | ||
Differentiation of Primary Affective Illness From Situational, Symptomatic, and Secondary Depressions | Q41604416 | ||
Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder | Q43011122 | ||
How can we realize the promise of personalized antidepressant medicines? | Q44045526 | ||
Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence | Q44845104 | ||
Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. | Q45068824 | ||
Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder | Q45079329 | ||
Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. | Q45924452 | ||
Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents | Q46612624 | ||
Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder | Q46694309 | ||
Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China | Q46776793 | ||
Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. | Q46922833 | ||
Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population. | Q47825016 | ||
Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits | Q47867995 | ||
Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia | Q48186144 | ||
Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance | Q48315286 | ||
Novel therapeutic approaches beyond the serotonin receptor | Q48385350 | ||
Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders | Q48401011 | ||
Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder | Q48411017 | ||
Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis | Q48582986 | ||
Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes | Q48649203 | ||
Subgenual prefrontal cortex abnormalities in mood disorders | Q48725544 | ||
The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence | Q49021766 | ||
Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. | Q51032825 | ||
The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? | Q51951357 | ||
Differential features between bipolar I and bipolar II disorder | Q57612992 | ||
Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group | Q67690092 | ||
Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatients | Q74452760 | ||
The emerging epidemiology of hypomania and bipolar II disorder | Q77700788 | ||
Recurrence of bipolar disorders and major depression. A life-long perspective | Q79077975 | ||
Changes in insight among patients with bipolar I disorder: a 2-year prospective study | Q80149571 | ||
P433 | issue | 2 | |
P304 | page(s) | 189-197 | |
P577 | publication date | 2013-10-09 | |
P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
P1476 | title | Genotype variant associated with add-on memantine in bipolar II disorder | |
P478 | volume | 17 |
Q39145461 | A Meta-Analysis of Memantine for Depression. |
Q48064476 | A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate |
Q33721019 | Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders |
Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
Search more.